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The amino acid sequence of stem bromelain, the major cysteine proteinase from pineapple stem is described. It shows 
that the enzyme is a member of the papain superfamily of cysteine proteinases, but is not very closely related to any 
other known member of this group. The sequence shows mutation or deletion of several residues that have been conserved 
in cysteine proteinases examined previously, including Asn-175 (papain). We suggest hat some of these changes have 
the effect of altering the active-site geometry of stem bromelain, and that this accounts for the resistance of the enzyme 
to inhibition by cystatins and E-64 [L-3-carboxy-2,3-trans-epoxypropionylleucylamido(4-guanidino)bu~neJ. 
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1. INTRODUCTION 
Stem bromelain is the major cysteine proteinase 
amongst a number of such enzymes present in the 
stem of the pineapple plant, Ananas CO~OSUS [I]. 
The enzyme is distinct both immunologically and 
in specificity from fruit bromelain, found in the 
fruit of the pineapple (Rowan, A.D. and Buttle, 
D.J., unpublished), and for the purposes of the 
present paper, we shall use the term bromelain ex- 
clusively to mean stem bromelain. Bromelain is un- 
usual amongst the cysteine proteinases that are 
homologous with papain in its weak inhibition by 
cystatin, a protein inhibitor from chicken egg- 
white, and by other related inhibitors (see section 
3). Bromelain is also inactivated only very slowly 
by E-64 [l]. 
Correspondence address: A. Ritonja, Department of Bio- 
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Although crude bromelain (a mixture of cysteine 
proteinases) is of considerable commercial impor- 
tance [2], bromelain as such has not been fully 
characterized. It is considered to be a glycoprotein 
consisting of a single polypeptide, and a single car- 
bohydrate side chain. Sequence data for somewhat 
over half the residues have been published ([3,4], 
review [5]), and a carbohydrate component has 
been studied [a]. The purpose of the present paper 
is to report the complete amino acid sequence of 
bromelain, and to discuss this in relation to the 
resistance of the enzyme to the inhibitors men- 
tioned above. 
2. EXPERIMENTAL 
The chemicals used for Edman degradation and amino acid 
analysis were of Sequenal grade from Applied Biosystems. 
Iodo[‘H]acetic acid was from Amersham, endoproteinase Lys- 
C from Boehringer Mannheim and protease V8 (S. aureas) from 
Miles Scientific (UK). All other chemicals were of analytical 
grade. 
Bromelain was purified from commercially obtained pineap- 
ple stem extract as in [l]. The protein was reduced with 2-mer- 
captoethanol in 6 M guanidine hydrochloride, and carboxy- 
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methylated with iodo[‘H]acetic acid. CNBr cleavage was per- 
formed with a 300-fold molar excess of reagent over methionyl 
residues in 70% (v/v) formic acid [7]. 
Peptides were purified by gel chromatography and HPLC on 
an Applied Biosystems RP-18 column eluted with aqueous 
acetonitrile containing trifluoroacetic acid. Samples were se- 
quenced with an Applied Biosystems model 470 A gas-phase se- 
quenator [El. Phenylthiohydantoin derivatives were identified 
on line with the 120 A HPLC [9]. 
Second-order ate constants for inactivation by iodoacetate 
and iodoacetamide were determined at pH 6.8, exactly as 
described for E-64 [l], except hat the concentration of dithio- 
threitol in the incubation (but not in the 5 min pre-incubation at 
40°C) was decreased to 0.2 mM. No allowance was made for 
reaction of the alkylating reagents with dithiothreitol. 
3. RESULTS AND DISCUSSION 
3.1. Amino acid sequence of bromelain 
Native bromelain eluted as a single symmetrical 
peak from a Sephacryl S-200 column (apparent M, 
about 24 000), and contained two sequences (fig. 1). 
The minor sequence (about 25%) started with Ala 
(residue 1 in fig.l), and the major (about 75%) 
with Val (residue 2). The reduced and carboxy- 
methylated protein was used for chemical cleavage 
with CNBr, which proved to be complete at 
methionyl bonds and partial (about 30%) at tryp- 
tophanyl bonds. The complete sequence was deter- 
mined from the CNBr-generated peptides, sub- 
fragments obtained by endoproteinase Lys-C 
cleavage of peptide CNl , and peptides from a pro- 
teinase V8 digest of the carboxymethylated protein 
(see fig.1). There was about 50% cleavage of the 
Asp-Pro (204-205) bond during the treatment with 
CNBr, which was expected in view of the acid- 
labile character of this bond. Non-specific cleavage 
with protease V8 on the carboxyl side of Gly-177 
was attributed to the long incubation necessitated 
by insolubility of the reduced and alkylated pro- 
tein. 
The results show that bromelain exists as a single 
polypeptide chain with 211 or 212 residues. The MI 
or the longer form of bromelain is calculated to be 
22 828 (fig. 1). Residue 117 was the only position in 
which no normal amino acid phenylthiohydantoin 
derivative was detected; hydrolysis of this 
derivative yielded aspartic acid, suggesting that it 
represented a glycosylated asparaginyl residue. 
This is consistent with the fact that residues 
117-119 are Asn-Glu-Ser, the -only potential 
glycosylation site in the molecule. The structure of 
an oligosaccharide from a bromelain preparation 
420 
has been reported [6]; this would have an Mr of 
about 1000, so that the total M, of bromelain may 
be about 23 800. 
The alignment of the amino acid sequence of 
bromelain with those of other cysteine proteinases 
(fig.2) shows unequivocally that the enzyme is a 
member of the papain superfamily, although it is 
not very closely related to any other known 
member. Percentages (in parentheses) of identical 
residues when the sequences are aligned as in fig.2 
decrease in the order: papaya proteinase III (43), 
actinidin (42), human cathepsin L (38), papain 
(38), human cathepsin H (33) and human cathepsin 
B (22). Bromelain resembles human cathepsin H 
[I I] in existing partially as a form having two 
rather than one residue prior to the conserved 
Pro-2 residue at the N-terminus. 
Bromelain is unusual amongst plant cysteine 
proteinases in its weak inhibition by the protein in- 
hibitor cystatin from chicken egg-white, and by 
other inhibitors of the cystatin superfamily in- 
cluding L-kininogen [16,17]. Rowan et al. [l] 
showed that the Ki of pure bromelain with chicken 
cystatin is not less than 3.6 x 10m5 M, at least seven 
orders of magnitude weaker than that of papain 
(< 5 x lo-” M: [18]). Bromelain is also distin- 
guished from most other cysteine proteinases by its 
very slow rate of inactivation by the active-site 
directed inhibitor, E-64, the second-order ate con- 
stant of 512 M-‘es-’ [l] contrasting with that of 
638 000 for papain [ 191. 
We have considered whether the amino acid se- 
quence of bromelain gives any indication of the 
reasons for its resistance to these inhibitors. The 
nature of the interaction between cysteine pro- 
teinases and cystatins is not known in detail, 
because it has not yet been possible to obtain 
crystals of enzyme-inhibitor complexes uitable for 
X-ray crystallography, but a very plausible pro- 
posal has been put forward by Bode et al. [20] on 
the basis of computer ‘docking’ of a shortened 
form of chicken cystatin in the active-site cleft of 
papain. In this model, one end of the cystatin 
molecule forms a wedge that fits accurately into the 
active-site cleft of papain. The wedge is con- 
structed of three segments of the cystatin polypep- 
tide chain: a segment close to the N-terminus in- 
volving the conserved Gly-9, a segment containing 
the conserved Gln-Xaa-Val-Gly sequence (residues 
53-57), and a segment from the C-terminus in- 
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1 10 20 30 40 SO 60 70 
AVPQSIDWBDYGAVTSVKNQNPCGACWAPAAIIIYE8IYKIKKGIL~PLSRQQVLDCAKGYGCKGGUEFR 
{Intact protein) 
AVPQSIDWRDYGAVTSVKNQNPCGACWAPAAIATVESIYKIKK--> 
(CRl) 
AVPQSIDWRDYGAVTSVKNQNPCGACWAFAAIATVESIYKIKKGIL--> 
(CgA) (CNC) (CRD) 
AVPQSIDX CCRR) AFAAIATVESIYKIKKGILEPLSEQQVLDCAKGYGCKGGX 
RDYGAVTSVKNQNPCGACX EFR 
(Kl) 
AVPQSIDWRDYGAVTSVK 
(K3) (K4) (K5) 
(K2) KGILEPLSEQQVLDCAK GGWEPR 
NQNPCGACWAFAAIATVESIYK GYGCK 
(El) (E3) (K4) (KS) (K6) 
AVPQSIX (R2) SIYKIKKGILEPLSE CAKGYGCKGGWE 
WRDYGAVTSVKNQNPCGACWAFAAIATVE QQvLx FR 
00 90 100 110 l 120 130 140 
AFRFIISNKGVASGAIYPYKAAKGTCKTDGVPNSAYITGYARVPRNNESSURYAVSKQPITVAVDANANF 
(CKDI (CN2) 
AFEFIISNKGVASGAIYPYKAAKGTCKTDGV--> HYAVSKQPITVAVDANANF 
(K5) (K7) 
AFEFIISNK (K6) GTCK (KS) 
GVASGAIYPYK TDGVPNSAYITGYARVPRNXESSX 
(E6) (ES) (El01 
APE (R7) GVPNSAYITGYARVPRNXE (R9) ANANF 
FIISNKGVASGAIYPYKAAKGTCKTX SSRMYAVSKQPITVAVX 
150 160 170 180 190 200 210 
QYYKSGVFNGPCGTSLNEAVTAIGYGQDSIIYPKKWGAKW6RAGYIRUARDVSSSS6ICGIAIDPLYPTLEB 
(CR21 (CUE) (cNF) (DP) 
QYYKSGVFNGPCGTSLNHAVTAIGYGQDSI--> GEAGYIRX (CN3) PLYPTLEE 
GAKX ARDVSSSSGICGIAIDPLYPTLEE 
{RlG) (El11 (El2) 
QYYKSGVFNGPCGTSLNHAVTAIGYGQX AKWGE (El3) 
SIIYPKKWG AGYIRHARDVSSSSGICGIAIDPLYPTLE 
Ala A 25 Gln Q 7 Leu L 6 Ser S 17 
Arg R 6 Glu E 9 Lys K 15 Thr T 9 
Asn N 10 Gly G 22 MetM 3 Trp W 5 
Asp D 8 His H 1 Phe F 6 Tyr Y 14 
cys c 7 Ile I 17 Pro P 11 Val V 14 
Total: 212 residues; M: 22,828. 
Fig. 1. Amino acid sequence and composition of bromelain, and strategy of the sequence determination. The amino acid sequence of 
S-[3H]carboxymethylated bromelain was determined by automated Edman degradation of the whole molecule, the eight CNBr peptides 
(CNl-CN3 and CNA-CNE), the eight endoproteinase Lys-C-generated peptides (Kl-KS) and 13 protease W-generated peptides 
(El-E13). The residues not directly identified in the individual peptides are marked (x). Cysteine residues were identified by the radioac- 
tivity of the S-[‘HJcarboxymethylated derivative. Asn-117 is the point of attachment of carbohydrate (indicated by *). 
eluding Pro-103 and Trp-104. There was already 
biochemical evidence that the first two of these 
segments are involved in the binding to papain 
[21,22], and a further study has implicated Trp-104 
~31. 
When the amino acid sequence of bromelain is 
421 
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sbrom 
Pap 
catHh 
catLh 
catBh 
PPIII 
actdn 
calph 
sbrom 
eae 
catHh 
catLh 
catBh 
PPIII 
actdn 
calph 
sbrom 
pap 
catHh 
catLh 
catBh 
PPIII 
actdn 
calph 
sbrom 
pap 
catHh 
catLh 
catBh 
PPIII 
actdn 
calph 
1 2 3 4 5 
123456abcd789012a345678901234567890123456789012345678901234567 
6 7 8 9 10 11 
8ab9012345678901ab2345abc6789012ab34567890123456789012345678901 
K---GYGCKGGWEFRA--FEFII--SNKGVAS--GAIYPYKAAKGTCKTDGVPNSAYIT-GYA 
~--Rs;:~,P~N~~~~~~yews :.--LQLV---AQY+.IHY--RNT..-; EGvQRY.:RsREKGPY .AK:..D. VR 
QDFNNi~~~~~~LPSQ~~,.--:i~~~~y~_L--Y-~~~~;-~-IMG--EDT-:‘;I~,~:rQGKD:,~y~.; FQPGKAICFVKDVAN 
GPQGNE.~~~~N’~~LMDy~.~--~~~yvQ--D~~~:~LD~~--EES~~~~~E~~EES~~~~~~yNPKySv~~~ND~~- ,,Fv 
GSMC;.-‘D~~~N’~~~~~~.yPAE.1’FIN:~~~TRKGLv~G~Ly~SHvGCR~~~~~,S~PP__ ::E’HBvNGS_RPP&;EG 
R--R~H’~~~~~~~~~~.~,~~~yPPy~~--L~~,~yvA--K~~~~~HL--RSK;,~~~~~~’~~~~~Q~~~~~~~~AKQ~~GGPIvK~,,S_.,vG 
RTQNTR;~~~~~:yITDd__..h’;~;:;:___N~G_..INT__DEN~,~~~~~~.~D~~~~~DvALQDQKyvTID’f;.D 
. . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
12 13 14 15 16 
23456789012345a678a901234567890123456789012a34abc5678a901234567 
17 18 19 20 21 
89abcde01234567890123456789012345a6789012345ab6789012 
Fig.2. Alignment of the bromelain (sbrom) sequence with those of papain (pap) [lo], human cathepsin H (catHh) [ll], human cathepsin 
L (catLh) [ 111, human cathepsin B (catBh) [ 121, papaya proteinase III (~~111) [ 131, actinidin (actdn) [ 141, and human calpain II (calph) 
[IS]. Residue numbers refer to the numbering scheme of papain [lo]. For several of the sequences, alternative residues have been 
reported at a few positions, as mentioned in the references cited. An insertion of 17 residues that occurs in cathepsin B between residues 
114 and 115 is deleted from the figure to save space. Segments of the calpain sequence that are not related to the other sequences are 
simply replaced by dots, for clarity. 
compared with those of papain, human cathepsin and the mutation of the highly conserved Ser-176 
H and human cathepsin L (all tightly bound by to Lys. Asn-175 has been found in all other papain 
cystatin [17]) as in fig.2, a number of differences homologues sequenced previously, with the excep- 
that must affect the geometry of the active-site cleft tion of the calpains, which incidentally are unaf- 
are apparent (fig.3). Perhaps the most striking is fected by most cystatins [17]. In papain, Asn-175 is 
the deletion of Asn-175 and two adjacent residues, hydrogen-bonded to His-159, and orients it for its 
422 
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Fig.3. Perspective drawing of the structure of papain @carbon atoms only, adapted from [24]), emphasising residues that we suggest 
may contribute to the conformation of the catalytic site, and are mutated or deleted in bromelain (closed circles). The broken lines mark 
the approximate line of the active-site cleft. Residues 25 and 159 are the cysteine and histidine residues that form the catalytic thiolate- 
imidazolium pair. 
catalytic function [5]. The substitution of Ser-21 by 
Pro, and of the highly conserved Ser-24 by Ala may 
well also affect the orientation of the catalytic 
Cys-25. In view of these factors, we suggest that the 
putative catalytic thiolate-imidazolium pair at the 
active site of bromelain is likely to have a different 
conformation from that in the cysteine proteinases 
that are tightly inhibited by cystatin. 
There are other replacements that modify the 
structure of the active-site cleft and the specificity 
subsites, but the residues concerned are generally 
not highly conserved, and moreover, we have not 
been able to identify any correlation between the 
substrate specificities of the cysteine proteinases 
and their susceptibility to inhibition by cystatin or 
E-64. 
3.2. Reactivity of the catalytic site of bromelain 
In view of the indications for an atypical disposi- 
tion of the catalytic groups in bromelain, we ex- 
amined the reactivity of the active site directly, us- 
ing iodoacetamide and iodoacetate. Negatively 
charged reactants are sensitive probes of the reac- 
tivity of the active sites of cysteine proteinases, and 
the thiolate-imidazolium ion pair of papain reacts 
at an enhanced rate with iodoacetate because of a 
favourable interaction between the positive im- 
idazolium ion of the ion pair and the negative car- 
boxylate of the alkylating reagent [25]. We deter- 
mined the second-order ate constants for inactiva- 
tion of papain by iodoacetate and iodoacetamide 
to be 1422 and 84 M-’ . s-l, respectively (a ratio of 
17.0); these values are in good agreement with 
those in the literature [25]. The corresponding 
values for bromelain were 17.7 and 5.5 M-’ . s-l 
(ratio 3.2), showing a much lower level of reactivi- 
ty, and a smaller discrimination in favour of the 
negatively charged reagent. 
In conclusion, it is clear that the geometry and 
reactivity of the catalytic site of bromelain are dif- 
ferent from those of cysteine proteinases that bind 
cystatins tightly and react rapidly with E-64. Since 
the earliest studies of chicken cystatin, it has been 
known that its binding to cysteine proteinases does 
not require an active catalytic site (review [ 17]), but 
it is known that some large substituents greatly 
423 
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weaken the interaction, showing that this is a struc- 
turally sensitive area for binding of this and related 
inhibitors. It has been pointed out that Cys-25 
resembles a high saddle-point hat subdivides the 
active-site cleft into two adjacent depressions [20]; 
in this case, one can easily imagine that a changed 
structure at this point might seriously affect the fit 
of the cystatin ‘wedge’ into the active-site cleft. 
E-64 inactivates papain by first forming a rever- 
sible, Michaelis-type complex, and then reacting 
covalently and irreversibly with Cys-25. We have 
no direct evidence as to which of these two steps is 
impaired in bromelain, to account for its slow in- 
teraction with E-64, but the simplest possibility is 
that the specific conformation of the catalytic site 
is responsible for the weak inhibition by E-64 as 
well as the loose binding of cystatins. 
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